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Abstract The molecular mechanisms that govern cell move-
ment are the subject of intense study, as they impact biologically
and medically important processes such as leukocyte chemotaxis
and angiogenesis, among others. We demonstrate that leukocyte
chemotaxis is prevented by the macrolide immunosuppressant
rapamycin, a speci¢c inhibitor of the mammalian target of ra-
pamycin (mTOR)/ribosomal p70-S6 kinase (p70S6K) pathway.
Both neutrophil chemotaxis and chemokinesis elicited by gran-
ulocyte-macrophage colony-stimulating factor (GM-CSF) were
strongly inhibited by rapamycin with an IC50 of 0.3 nM. Inhi-
bition, although at a higher dose, was also observed when the
chemoattractant was interleukin-8. As for the mechanism, rapa-
mycin targeted the increase of phosphorylation of p70S6K due
to GM-CSF treatment, as demonstrated with speci¢c anti-
p70S6K immunoprecipitation and subsequent immunoblotting
with anti-T421/S424 antibodies. Rapamycin also inhibited GM-
CSF-induced actin polymerization, a hallmark of leukocyte mi-
gration. The speci¢city of the e¡ect of rapamycin was con¢rmed
by the use of the structural analog FK506, which did not have a
signi¢cant e¡ect on chemotaxis but e¡ectively rescued rapamy-
cin-induced p70S6K inhibition. This was expected from a com-
petitive e¡ect of both molecules on FK506-binding proteins
(FKBP). Additionally, GM-CSF-induced chemotaxis was com-
pletely (s 90%) blocked by a combination of rapamycin and the
MAPK kinase (MEK) inhibitor PD-98059. In summary, the
results presented here indicate for the ¢rst time that rapamycin,
at sub-nanomolar concentrations, inhibits GM-CSF-induced
chemotaxis and chemokinesis. This serves to underscore the
relevance of the mTOR/S6K pathway in neutrophil migration.
> 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
During in£ammation and infection, neutrophil phagocyto-
sis and killing of invading pathogens begins by adhesion of
these cells to the capillary endothelium followed by diapedesis
and the ultimate arrival into the in£amed/infected tissues.
Chemotaxis and phagocytosis are enhanced by the presence
of hematopoietic cytokines and chemokines. Granulocyte-
macrophage colony-stimulating factor (GM-CSF) and inter-
leukin-8 (IL-8) are particularly e¡ective in enhancing neutro-
phil functionality. As for the molecular signaling mechanism
of chemotaxis, a role for phosphatidylinositol 3-kinase (PI3K)
and Akt/PKB in regulating neutrophil migration has been
demonstrated [1^4]. Despite this knowledge of the upstream
members of the PI3K pathway, the physiological role of the
downstream links (namely, mTOR (mammalian target of ra-
pamycin) and p70S6K (ribosomal p70-S6 kinase)), has not
been examined directly in hematopoietic cells. The immuno-
suppressant rapamycin has emerged as a very useful agent to
ascertain whether the mTOR/S6K pathway is involved in a
particular signaling initiated by a stimulus of interest. For
instance, thrombin-induced formation of stress ¢bers in 3T3
¢broblasts is associated with the presence of p70S6K and is
inhibited by rapamycin [5].
Rapamycin binds in vitro to and inhibits the kinases TOR1/
2 (in yeast) and mTOR (in mammalian cells) [6]. It also par-
tially inhibits in situ insulin/mitogen-stimulated phosphoryla-
tion of eIF-4E and the ribosomal p70S6K [7]. mTOR phos-
phorylates p70S6K, which in turn phosphorylates the S6
protein in the 40S small ribosomal subunit. This is needed
for protein translation and for new ribosome formation, hence
the originally described inhibitory e¡ect of rapamycin in cell
growth. To exert its action on mTOR, rapamycin binds to the
immunophilin FK binding protein-12 (FKBP12), which is the
soluble receptor for another immunosuppressant drug,
FK506. FK506, an FKBP12-binding compound related to
rapamycin, does not inhibit mTOR [8,9]. Rapamycin prevents
neutrophil Ca2þ-associated activation [5] and in¢ltration that
is associated with accelerated rejection in cardiac tissue trans-
plants [10].
Rapamycin is currently being tested for its potential ther-
apeutic properties [11^14] as an immunosuppressant for organ
transplants, in cancer (currently in Phase II clinical trials) as
having anti-growth e¡ects, directly on solid tumors and as
having anti-angiogenic activity (a¡ecting endothelial cells),
in rheumatoid arthritis (as it a¡ects synovial ¢broblasts) and
in heart disease, in ischemic hypertrophy and in restenosis to
prevent re-occlusion of lesions by vascular smooth muscle
cells after balloon angioplasty (currently in Phase III clinical
trials). The therapeutic and the physiological mechanisms of
inhibition in vivo are under current study. In this respect,
Bohler et al. [15] have demonstrated that intake of a 2-hy-
droxy-ethyl derivative of rapamycin (SDZ RAD) by renal
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allograft recipients with stable graft function, results in a sig-
ni¢cant, albeit transient, reduction in T-cell proliferation. Co-
stimulation of peripheral blood mononuclear cells from
healthy volunteers with the rapamycin derivative and another
immunosuppressant, cyclosporine A, revealed an additive ef-
fect of both agents on anti-CD3-driven T-cell proliferation
[15].
With regard to cell migration and, speci¢cally, to neutrophil
chemotaxis, it should be noted that a chemotactic response to
GM-CSF alone or in combination with chemoattractants
from the host (like IL-8) or from the invading micro-organ-
isms (like FMLP) would be bene¢cial to the phagocytic cell.
Inasmuch as cell migration is crucial to the host (and some-
times can make the di¡erence between life and death), there
are well-described instances in which side e¡ects of in£amma-
tion are highly undesirable. Examples include: cellulitis, ar-
thritis, gout, asthma, ischemia-reperfusion injury and the for-
mation of the atherosclerotic plaque. Thus, the interest in
drugs that could be used to reduce in£ammation injury in
these conditions by limiting leukocyte migration is under-
standable. Here, we provide evidence for the ¢rst time that
neutrophil migration is strongly inhibited by rapamycin and
present data that help us understand the underlying cell sig-
naling mechanism for this important leukocyte functionality.
2. Materials and methods
2.1. Materials and antibodies
GM-CSF and IL-8 were from RpD Systems (Minneapolis, MN,
USA); 24-well Transwell membrane tissue plates (with 6.5-mm diam-
eter, 5-Wm pore inserts) were from Corning Costar (Cambridge, MA,
USA); FMLP, PKA inhibitor, calphostin, anti-rabbit IgG (agarose
beads), trypan blue, phalloidin^£uorescein isothiocyanate (FITC) con-
jugate from Amanita phalloides were from Sigma (St. Louis, MO,
USA); ‘FACS FLOW’ bu¡er was from Fisher (Hanover Park, IL,
USA); rapamycin and FK506 were from Calbiochem (San Diego,
CA, USA); PD-98059 was from BioMol (Plymouth Meeting, PA,
USA); anti-p70S6K and anti-phospho(T421/S424)-p70S6K antibodies
(polyclonal) used for immunoprecipitation and immunoblotting were
from Cell Signaling (Beverly, MA, USA).
2.2. Cells
Peripheral blood neutrophils were isolated based on a protocol
described by English and Andersen [16]. Between 50 and 55 ml of
blood was collected from the antecubital vein of healthy individuals
(who signed an Institutional Review Board-approved consent form)
using sodium citrate as anticoagulant. Blood was mixed with 15 ml of
6% dextran, allowed to settle, and the plasma and bu¡y coat were
removed and spun down at 800Ug for 5 min. The pellet was resus-
pended in 35 ml of saline and centrifuged again for 15 min at 10‡C in
a Ficoll-Histopaque discontinuous gradient. Neutrophils were recov-
ered and contaminating erythrocytes were lysed by hypotonic shock.
Cells were washed and the pellet was resuspended at a concentration
of 5U106 cells/ml in fresh RPMI at 2U106 cells/ml at the time of the
experiment, and used within 5 h after isolation.
2.3. Chemotaxis functional assay in Transwell plates
Neutrophils (3U106) resuspended in chemotaxis bu¡er (RPMI+
0.5% bovine serum albumin) in Eppendorf tubes were incubated
with inhibitors (when required) at 37‡C on a rocker platform for 30
min. After this, cells were placed in the upper chambers or ‘inserts’ of
Transwell plates that are separated from the lower wells by a 6.5-mm
diameter, 5-Wm pore, Nucleopore polycarbonate membrane. For the
study of chemotaxis, GM-CSF or IL-8 was added in 0.5 ml chemo-
taxis bu¡er to the lower wells of Transwell plates [17]. For the study
of chemokinesis, GM-CSF or IL-8 was added in 0.5 ml chemotaxis
bu¡er to the lower chambers and in 200 Wl chemotaxis bu¡er to the
upper chambers. In either case, the Transwell plates were incubated
for 45 min at 37‡C under a 5% CO2 atmosphere. The number of cells
that migrated to the lower wells was calculated by counting four ¢elds
of duplicate 20-Wl aliquots on a microscope using a hemocytometer.
Viability (by trypan blue exclusion) at the end of the assay in both
chambers remained s 95S2%, even in the presence of the inhibitor
rapamycin, ruling out a toxic e¡ect.
2.4. F-actin measurement by £ow cytometry
Neutrophils were stained with phalloidin^FITC as described in [18]
with some modi¢cations. Brie£y, F-actin polymerization was initiated
in vivo by the addition of GM-CSF to a neutrophil cell suspension
(5U106 cells/ml) for 5 min at 37‡C. After this, 0.2-ml aliquots were
taken and mixed with 1 ml of pre-chilled ¢xing solution (two parts of
double-concentrated phosphate bu¡er, pH 7.4, one part of 20% form-
aldehyde and one part of 75% glycerol in water). Samples were stored
at 380‡C until ready for £ow cytometry. At that time, samples were
thawed and spun down for 5 min at 600Ug in a refrigerated Eppen-
dorf microfuge. Pellets were resuspended in freshly prepared F-actin
staining solution (35 Wl of a 3.3-Wg/ml methanol FITC^phalloidin
stock plus 315 Wl H2O), and stained in the dark for 30 min at room
temperature. Samples were centrifuged as above and pellets were re-
suspended in 1 ml of ‘FACS FLOW’. They were then analyzed by
£ow cytometry on a FACSCAN Becton p Dickinson £ow cytometer
at 488 nm excitation wavelength. Data were analyzed using Cell Quest
software. The relative F-actin content was expressed in comparison
with resting cells that received no treatment. Results of £uorescence
intensity are shown in a logarithmic scale as in [18,19].
2.5. p70S6K analyses
2.5.1. Phosphorylation. Stimulation of neutrophils (3U106 cells/ml
in RPMI) with appropriate agents was terminated by centrifugation
(14 000Ug, 15 s) and resuspension of pellets in boiling sodium dodecyl
sulfate (SDS) solution (1% SDS in 10 mM Tris, pH 7.4). Samples were
boiled in a heat block for 10 min with frequent vortexing to achieve
complete dissolution, taken to an ice bucket and mixed with 0.3 ml
cold ddH2O and 0.4 ml cold, Triton X-100-based, lysis bu¡er (12 mM
Tris^HCl, pH 7.2, 0.75 mM NaCl, 100 WM sodium orthovanadate, 10
mM phenylmethylsulfonyl £uoride, 0.2 mM L-glycerophosphate, 5 Wg/
ml each of aprotinin, pepstatin A and leupeptin, and 0.12% Triton
X-100). The resulting cell lysates were used for immunoprecipitation
and immunoblotting, as in [20] with anti-phospho-T421/S424-p70S6K
antibodies.
2.5.2. Enzyme activity. Ribosomal p70S6K enzymatic activity was
quanti¢ed by using an immunocomplex kinase assay as reported pre-
viously [17] tailored for p70S6K. Cell lysates were obtained in a Tri-
ton X-100-based lysis bu¡er and immunoprecipitated with anti-
p70S6K antibodies. Immune complex beads were mixed with 75 WM
of the phosphoacceptor peptide substrate KKRNRTLTK in freshly
prepared kinase bu¡er (13.4 mM HEPES, pH 7.3, 25 mM MgCl2, 30
WM Na2VO3, 5 mM p-nitrophenyl phosphate, 2 mM EGTA, 2 WM
cAMP-dependent kinase inhibitor TTYADFIASGRTGRRNAIHD,
0.420 WCi [Q-32P]ATP (7 nM), and 68 WM unlabeled ATP). The reac-
tion was carried out at 37‡C for 20 min in a rotator and terminated by
blotting 40 Wl of the reaction mixture onto P81 ion exchange chroma-
tography cellulose phosphate papers.
2.6. Statistical analysis
Data are presented as the meanSS.E.M. The di¡erence between
means was assessed by the single-factor analysis of variance (AN-
OVA) test. Probabilities of less than 0.01 (P6 0.01) or less than
0.05 (P6 0.05) were considered to indicate signi¢cant di¡erences.
3. Results
3.1. Leukocyte migration is inhibited by rapamycin
We have studied neutrophil migration in Transwell plates
and have observed that pre-incubation of neutrophils with
rapamycin at a sub-nanomolar concentration strongly inhibits
chemotaxis of these cells towards either GM-CSF or IL-8.
The dose^response experiment in Fig. 1A demonstrates that
rapamycin inhibited GM-CSF-induced chemotaxis with an
IC50 of 0.3 nM and IL-8-induced chemotaxis with an IC50
of 2 nM. Interestingly, rapamycin also inhibited control mi-
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gration, particularly at 10 nM and above, with viability of
cells remaining high (s 90%, as per trypan blue exclusion).
We next designed an experiment to ascertain whether or not
the inhibition by rapamycin was reversible (Fig. 1B). After
incubation with rapamycin, cells were washed and then stimu-
lated with GM-CSF as before. In this case, the inhibitory
e¡ect of rapamycin is attenuated but never completely disap-
pears, indicating that once it enters the cell, some of the e¡ect
is irreversible, particularly at concentrations v 5 nM. Chemo-
kinesis (random migration) is also very sensitive to rapamycin,
which inhibited GM-CSF-induced chemokinesis with an IC50
of 0.2 nM, and it also inhibited IL-8-induced chemokinesis
with an IC50 of 0.5 nM (Fig. 1C). The inhibitory e¡ect re-
mained even after washing o¡ rapamycin and allowing the
cells to migrate in Transwell plates for up to 1 h.
3.2. E¡ects of rapamycin on S6K phosphorylation, kinase
activity and actin polymerization
Since it is known that rapamycin inhibits the phosphoryla-
tion of mTOR as well as that of p70S6K (one of its sub-
Fig. 1. E¡ect of rapamycin on cell migration. A: Freshly isolated
human neutrophils were resuspended in RPMI-based chemotaxis
bu¡er at a density of 3U106 cells/ml and incubated with the indi-
cated concentrations of rapamycin for 30 min at 37‡C. Next, ali-
quots containing 6U105 cells were placed in the upper ‘insert’ wells
of Transwell plates and exposed to either 7 nM GM-CSF or 10 nM
IL-8 for 45 min at 37‡C under a 5% CO2 atmosphere. B: E¡ect of
washing rapamycin o¡ (indicated in the ¢gure by ‘w’). Cells were in-
cubated with the indicated concentrations of rapamycin for 30 min
and then spun down at 600Ug for 5 min. Supernatants were deca-
nted and pellets were resuspended in fresh chemotaxis bu¡er before
moving them to the Transwell plates. C: Dose^response of rapamy-
cin on IL-8- and GM-CSF-induced chemokinesis and e¡ect of wash-
ing o¡ the drug. Chemokinesis was accomplished by placing the cy-
tokine (either 7 nM GM-CSF or 10 nM IL-8) in both the lower
wells and the upper inserts wells of Transwell plates. 100% repre-
sents 21S 1U104 cells/ml for Control, 70S 6U104 cells/ml for GM-
CSF and 132S 8U104 cells/ml for IL-8.
Fig. 2. E¡ect of rapamycin on GM-CSF-stimulated p70S6K phos-
phorylation and enzymatic activity. Neutrophils were incubated with
10 nM rapamycin for 30 min, followed by a short (5 min) incuba-
tion with 7 nM GM-CSF and cell lysates in boiling SDS were gen-
erated and immunoprecipitation with anti-p70S6K followed. Result-
ing immunocomplexes were used for immunoblotting with anti-
phospho-T421/S424-p70S6K antibodies (panel A) or with anti-p70S6K
antibodies to show equal protein loading (panel B). C: Detection of
p70S6K enzymatic activity and its modulation by GM-CSF and ra-
pamycin. Cells were incubated S rapamycin for 30 min and then
subjected to GM-CSF incubation. Cell lysates were derived and im-
munoprecipitated. Immunocomplex beads were assayed for p70S6K
activity against the S6 kinase substrate peptide KKRNRTLTK. Re-
sults are the meanSS.E.M. of three independent experiments per-
formed in duplicate. 100% represents 1052S 77 dpm.
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strates), we next ran controls to ascertain if the concentration
of rapamycin shown to inhibit chemotaxis was able to a¡ect
its molecular target(s). For this, we concentrated on GM-
CSF, since data in Fig. 1 indicate that chemotaxis and chemo-
kinesis are more sensitive to rapamycin when the stimulant is
GM-CSF vs. IL-8, and since chemoattractants other than
GM-CSF produce a measurable, but low, e¡ect on p70S6K
phosphorylation1. Fig. 2A shows that GM-CSF induced an
increase in T421/S424 phosphorylation of p70S6K and that ra-
pamycin was able to negate that e¡ect. This was seen in the
Western blots as a change in electrophoretic mobility (indica-
tive of a loss of phosphate, as demonstrated in [21]) and as a
diminished signal to the antibody in the rapamycin+GM-CSF
lane. Fig. 2B indicates that all the changes alluded to above
are observed in the presence of equal levels of protein loading
with an anti-p70S6K antibody that detects the unphosphory-
lated form.
We next measured the activity of this enzyme in vitro. In-
cubation of neutrophils with GM-CSF resulted in an increase
of p70S6K activity and pre-treatement with rapamycin caused
inhibition of the enzymatic activity of p70S6K (Fig. 2C) that
paralleled the results of phosphorylation indicated in Fig. 2A.
All this serves to demonstrate that, in neutrophils, rapamycin
targets p70S6K in conditions in which cell migration is inhib-
ited. We next investigated if rapamycin had an inhibitory
e¡ect on actin polymerization, a hallmark of cell migration.
Fig. 3A shows that GM-CSF caused an increase in F-actin
polymerization, as seen by a displacement to the right of the
log £uorescence values on the x-axis. While rapamycin by
itself had no e¡ect on F-actin polymerization (Fig. 3B), it
inhibited the GM-CSF-induced changes, as evidenced by a
displacement to the left of the log £uorescence values (Fig.
Fig. 3. E¡ect of rapamycin on GM-CSF-stimulated F-actin polymerization. Several sets of neutrophil suspensions were incubated at 37‡C in
the presence or the absence of 7 nM GM-CSF for 5 min (panel A); or with either 50 nM rapamycin or 50 nM FK506 (panel B) for 30 min;
or with the indicated concentrations of rapamycin (panels C,D) or FK506 (panels E,F) for 30 min prior to the addition of GM-CSF, and fur-
ther incubated for 5 min. All stimulations were stopped at the end of the indicated lengths of time by ¢xing cells in formaldehyde. 200-Wl sam-
ples of 1U104 cells were incubated with phalloidin^FITC and analyzed by £ow cytometry. x-axes: log £uorescence; y-axes: relative cell num-
ber.
1 Gomez-Cambronero, J., Horn, J., Paul, C. and Baumann, M., un-
published observations.
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3C,D). However, for the rapamycin e¡ect to be observed,
concentrations of the drug larger than those used to inhibit
cell migration were needed (10 nM and above vs. 1 nM). To
con¢rm the speci¢city of this e¡ect, we repeated the experi-
ment by pre-incubation of neutrophils with FK506, a struc-
tural analog of rapamycin, an FKBP12-binding compound,
that lacks the ability to inhibit mTOR. In the case of
FK506, no inhibition was observed at the doses tested (Fig.
3E,F).
3.3. FK506, but not MEKi, rescues the inhibition caused by
rapamycin in chemotaxis
One of the hallmarks of the study of speci¢city of rapamy-
cin is that its e¡ect is prevented (or once it is produced, it can
be ‘rescued’) by treatment of cells with the structural analog
FK506 [22^25]. In our hands, such was the case: the inhibi-
tory e¡ect of rapamycin on chemotaxis was reversed by pre-
incubating cells with FK506 prior to rapamycin (Fig. 4A,
group of bars to the left), indicating that FK506 prevents
rapamycin inhibition at a 1:10 (and greater) rapamy-
cin:FK506 molar ratio. This action was unique to FK506,
since a rescue was not observed with mitogen-activated pro-
tein kinase kinase inhibitor (MEKi; Fig. 4A, group of bars to
the right). In fact, the incubation with MEKi drove the exist-
ing rapamycin inhibition to pre-stimulation levels, since the
di¡erence between 5 or 10 WM MEKi and control (the two
bars at the furthermost right and the bar at the furthermost
left) was not signi¢cant. However, the di¡erences between
rapamycin alone and rapamcycin plus 5 or 10 WM MEKi
were signi¢cant (*** in Fig. 4A, with P6 0.05). This might
suggest that cell migration also requires a positive input from
the Ras/MAPK pathway; (actin polymerization was also in-
hibited by MEKi and the e¡ect was greater by a combination
of MEKi and rapamycin [data not shown]). We know that
another element could be up-regulating p70S6K activity: a
positive feedback from the MAPK pathway, since we have
recently demonstrated a crosstalk between these two major
pathways [26]. Note, however, that rapamycin is a much
stronger inhibitor of leukocyte migration, since it produced
its e¡ect in the sub-nanomolar range, while MEKi inhibited
Fig. 4. FK506 and MEKi. A: E¡ect on neutrophil chemotaxis. Neutrophils were incubated at 37‡C with the indicated concentrations of
FK506 (group of bars to the left) or MEKi (group of bars to the right) for 30 min, followed by an additional 30-min incubation with rapamy-
cin. Cells were then placed in the upper wells of Transwell plates and allowed to migrate against GM-CSF (where indicated) for 45 min. The
di¡erences between control and GM-CSF-induced chemotaxis (*), as well as the inhibition caused by rapamycin over GM-CSF (**) were signif-
icant (P6 0.01). The further inhibition by MEKi of the rapamycin inhibition (***) was also signi¢cant (P6 0.05). Treatment with MEKi in the
absence of GM-CSF exhibited curves indistinguishable from controls (as in Fig. 3B). B: E¡ect on actin polymerization. Cells were treated with
either MEKi alone or with a combination of MEKi and rapamycin, stimulated with GM-CSF for 5 min, ¢xed, incubated with phalloidin^
FITC and analyzed by £ow cytometry.
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at the sub-micromolar range. A con¢rmation of the coopera-
tive nature of MEKi and rapamycin is given in Fig. 4B, where
actin polymerization is further inhibited when both inhibitors
are together (even at low concentrations), as given by the
larger di¡erence in £uorescence intensity as compared to con-
trols.
4. Discussion
We have shown in this study for the ¢rst time in cells of the
hematopoietic system that both chemotaxis and chemokinesis
were inhibited by the antibiotic macrolide and immunosup-
pressant rapamycin. This inhibition is very potent, particu-
larly chemokinesis, that had an IC50 of V300 pM and was
complete at 3^10 nM. We should highlight that the evidence
for this inhibition takes place in a whole-cell setting, demon-
strating an e¡ect on a fundamental physiological function of
the leukocyte. These potencies are in contrast to MEKi, the
other agent that we have described here as being inhibitory of
cell migration, but the concentrations of MEKi needed to
hamper cell migration were in the sub-WM range [26].
A previous report has indicated a possible link to p70S6K
in lipopolysaccharide (LPS)-induced nitric oxide production
in macrophages [27]. The authors have observed that rapamy-
cin inhibits p70S6K (both basal and LPS-activated compo-
nents) and it also inhibits mobility shift (¢gure 3B of their
study). Although the e¡ects of rapamycin on p70S6K and
cytoskeleton are known [27^29], this study provides the ¢rst
evidence for the inhibition of cell migration by rapamycin.
Here we have indicated the inhibition of cell migration in
conditions in which both phosphorylation and enzymatic ac-
tivity are inhibited. Rapamycin being an inhibitor of the
mTOR/S6K pathway, it is therefore reasonable to conclude
that that pathway should have a key role in neutrophil che-
motaxis and chemokinesis.
Although rapamycin is usually described as a speci¢c inhib-
itor of mTOR, this kinase is a direct stimulant of p70S6K,
which serves as its physiological substrate [30,31]. The fact
that rapamycin binds to the immunophilin FKBP12 raises
the possibility that any inhibitory e¡ect on chemotaxis ob-
served is through disruption of an important FKPB12 com-
plex, independent of e¡ects on mTOR/S6K. To address the
speci¢city of rapamycin we treated neutrophils with FK506,
an FKBP12-binding compound, related to rapamycin, that
lacks the ability to inhibit mTOR [23^26]. Since FK506 did
not inhibit actin polymerization, it suggested that the e¡ect of
rapamycin was directly through the mTOR pathway. Of note
are also the results indicating that FK506 has a preventive
e¡ect on the inhibitory action of rapamycin (Fig. 4A) in
whole cells.
We have demonstrated that rapamycin completely inhibits
chemotaxis at V1 nM (Fig. 1), but a minimum of 10 nM is
required to inhibit actin polymerization (Fig. 3). The reason
for this could be that there are either several pools of p70S6K
inside the cell, each performing di¡erent functions and each
with potentially di¡erent rapamycin sensitivities, or that the
concentration of intracellular FKBP12 is much higher than
that of mTOR (P. Dennis, personal communication). In the
latter scenario, rapamycin at low concentrations (6 1 nM)
could already saturate mTOR-dependent actin polymeriza-
tion, while only minimally a¡ecting processes dependent on
FKBP12. High concentrations (s 10 nM) of rapamycin can
block FKBP12 and, presumably, F-actin polymerization that
might be dependent on both FKBP12 and mTOR. In any
event, actin polymerization remains a candidate for the e¡ect
of rapamycin on neutrophils. A precedent for a connection
between rapamycin and the cytoskeleton has been given in
[28], who have demonstrated that rapamycin at 20 nM inhib-
its myogenesis and concomitant muscle cell di¡erentiation,
and by [29], who demonstrated that TOR2 in yeast is impor-
tant for polarized distribution of the actin cytoskeleton, in
addition to its primary function as an e¡ector of G1 cell cycle
progression.
The understanding of the blockage of neutrophil migration
by inhibitors that target the mTOR/S6K pathway as demon-
strated in this study will not be con¢ned to the physiology of
leukocytes but, rather, will have a much broader e¡ect, in-
volving the central paradigm in cell biology of cell migration.
Migration of endothelial cells is key in the process of angio-
genesis and tumor growth; migration of vascular smooth cells
re-occludes arteries after angioplasty of atherosclerotic coro-
nary arteries ; and migration of synovial ¢broblasts is a hall-
mark of rheumatoid arthritis.
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